Kai Wiechen

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

Uğur Şahin, Ö. Türeci, Georgy M. Manikhas et al. · Annals of Oncology · 2021 · 338 citations · Full text

Gastrointestinal Oncology, Medicine, Gastro-oesophageal Adenocarcinoma +10

Caveolin-1 Is Down-Regulated in Human Ovarian Carcinoma and Acts as a Candidate Tumor Suppressor Gene

Kai Wiechen, Luda Diatchenko, Alexander I. Agoulnik et al. · American Journal Of Pathology · 2001 · 277 citations · Full text

Human Ovarian Carcinoma, Medicine, Pathology +7

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

Ö. Türeci, Uğur Şahin, Henning Schulze‐Bergkamen et al. · Annals of Oncology · 2019 · 232 citations · Full text

Down-Regulation of Caveolin-1, a Candidate Tumor Suppressor Gene, in Sarcomas

Kai Wiechen, Christine Sers, Alexander I. Agoulnik et al. · American Journal Of Pathology · 2001 · 168 citations · Full text

Tumor Biology, Medicine, Pathology +6

Loss of Gelsolin expression in human ovarian carcinomas

Aurelia Noske, Carsten Denkert, Hagen Schober et al. · European Journal of Cancer · 2005 · 80 citations

Medicine, Gynecology, Gelsolin Expression +4